FINWIRES · TerminalLIVE
FINWIRES

HKG:0013

7 stories mentioning HKG:0013Updated 3d ago

Every FINWIRES story that references HKG:0013, newest first.

What's the latest news on HKG:0013?

Asia

Market Chatter: US Considers Rules Allowing American Investment in Chinese Drugs

The U.S. Department of Treasury is planning to introduce rules that would allow American pharmaceuticals to invest in the licensing of Chinese drugs, Reuters reported Sept. 18, citing sources.The rules, which are still subject to change, would cover most of the new drugs under development, except those related to pathogens or biotechnology that can be potentially weaponized, the sources told the news outlet.The news sparked positive sentiment towards Chinese pharmaceuticals on Monday, with Akeso (HKG:9926) jumping 10%, Sino Biopharmaceutical (HKG:1177) climbing 8%, CSPC Pharmaceutical Group (HKG:1093) rising 7%, Innovent Biologics (HKG:1801) inching 6% higher and HUTCHMED (HKG:0013) increasing 4% at the close.The U.S. Treasury Department did not immediately respond to' request for comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Hang SengShanghai Composite^SZSEHKG:0013HKG:1093HKG:1177HKG:1801HKG:9926
Asia

Hong Kong Stocks Fall on Thursday, Amid Bond Selloff, Rate Fears; HUTCHMED Jumps 14%

Hong Kong stocks closed lower on Thursday as rising bond yields and oil prices increased concerns over U.S. interest rates and monetary policy.The Hang Seng Index fell 97.90 points, or 0.4%, to close at 25,213.31, while the Hang Seng China Enterprises Index dropped 64.86 points, or 0.8%, to 8,385.24.Global bond prices fell, with U.S. Treasury yields reaching their highest levels since 2023, while higher oil prices added to inflation concerns.Investors also remained cautious amid renewed U.S.-Iran attacks and awaited Friday's U.S. payrolls report for clues on the Federal Reserve's next move. Markets have raised the odds of a 25-basis-point rate hike this month to about 62% from 37% a week ago, according to a Reuters report.In corporate developments, HUTCHMED (China) (HKG:0013) jumped more than 14% after agreeing to grant a GSK subsidiary worldwide rights, excluding Mainland China, Hong Kong, Macau and Taiwan, to develop and commercialize its experimental cancer drug HMPL-A830 for up to $1.30 billion.Separately, Impact Therapeutics (HKG:7630) rose 12% after CEO Sui Xiong Cai bought 100,000 shares for HK$1.6 million.

Hang SengHKG:0013HKG:7630
Asia

HUTCHMED Licenses Cancer Drug to GSK for Up to $1.30 Billion; Shares Up 12%

HUTCHMED (HKG:0013) agreed to grant a GSK subsidiary worldwide rights, excluding Mainland China, Hong Kong, Macau, and Taiwan, to develop and commercialize its experimental cancer drug HMPL-A830 for up to $1.30 billion.The deal includes a $110 million upfront payment, potential development, regulatory and commercial milestones of up to $1.19 billion, and royalties on net sales, according to a Thursday Hong Kong exchange filing.HUTCHMED will lead the initial global Phase I program, expected to start in the second half of 2026, while GSK will take over subsequent development and commercialization outside the retained territories. The initial program will focus on colorectal, pancreatic and lung cancers.Shares of the company rose 12% in recent trade.

HKG:0013
Asia

HUTCHMED Sees Positive High Level Results in Lung Cancer Drug Combo Trial

HUTCHMED (China) (HKG:0013) announced positive high-level results from its SANOVO China phase ІІІ trial in treatment-naïve patients with non-small cell lung cancer, according to a Monday Hong Kong bourse filing.ORPATHYS plus TAGRІSSO significantly improved progression-free survival versus TAGRІSSO alone in both high MET and intention-to-treat patient populations.The combination also showed an encouraging clinical benefit in overall survival in both populations, which was a secondary endpoint of the trial.

HKG:0013
Asia

Hutchmed's Savolitinib Combo Improves Survival in Lung Cancer Trial; Shares Jump 5%

HUTCHMED (China) (HKG:0013) said its savolitinib combination with AstraZeneca's osimertinib significantly improved progression-free and overall survival in a Phase III lung cancer trial.The SAFFRON trial evaluated patients whose cancer had progressed after osimertinib treatment and whose tumors had high levels of MET, according to a Monday Hong Kong exchange filing. The safety profile was consistent with the known effects of the two drugs, with no new safety findings.Shares of the company jumped nearly 5% in recent trade.

HKG:0013
Asia

Innovent Biologics, Hutchmed's Drug Combination Application to Treat Renal Cell Carcinoma Gets China Nod

Innovent Biologics (HKG:1801) and Hutchmed (China) (HKG:0013) obtained approval for a new drug application for the combination of TYVYT and ELUNATE from China's National Medical Products Administration, according to a Thursday filing with the Hong Kong bourse.The combination is intended to treat patients with locally advanced or metastatic renal cell carcinoma.Hutchmed co-developed ELUNATE with Eli Lilly and Company, while TYVYT was co-developed by Innovent Biologics and Eli Lilly.

HKG:0013HKG:1801
Asia

Hutchmed's Application for Immune Disease Drug Accepted, Granted Priority Review in China

Hutchmed (China)'s (HKG:0013) new drug application for sovleplenib for the treatment of adult patients with warm antibody autoimmune hemolytic anemia has been accepted for review and granted priority review by China's National Medical Products Administration.Sovleplenib is being developed for the treatment of immune diseases and hematological malignancies, according to a Wednesday Hong Kong bourse filing.

HKG:0013

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:0013 in your portfolio
WheelAI
WheelAI
Analyze HKG:0013 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:0013